1895 related articles for article (PubMed ID: 32716739)
21. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
Ikeda M; Okusaka T; Mitsunaga S; Ueno H; Tamai T; Suzuki T; Hayato S; Kadowaki T; Okita K; Kumada H
Clin Cancer Res; 2016 Mar; 22(6):1385-94. PubMed ID: 26500236
[TBL] [Abstract][Full Text] [Related]
22. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Makker V; Colombo N; Casado Herráez A; Santin AD; Colomba E; Miller DS; Fujiwara K; Pignata S; Baron-Hay S; Ray-Coquard I; Shapira-Frommer R; Ushijima K; Sakata J; Yonemori K; Kim YM; Guerra EM; Sanli UA; McCormack MM; Smith AD; Keefe S; Bird S; Dutta L; Orlowski RJ; Lorusso D;
N Engl J Med; 2022 Feb; 386(5):437-448. PubMed ID: 35045221
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis.
Changez MIK; Khan M; Uzair M; Tahir MF; Mohsin M; Hussain AF; Saqib V; Molani MK; Ahmed AH; Khalid S
J Gastrointest Cancer; 2024 Mar; 55(1):467-481. PubMed ID: 38095799
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
Gaspar N; Venkatramani R; Hecker-Nolting S; Melcon SG; Locatelli F; Bautista F; Longhi A; Lervat C; Entz-Werle N; Casanova M; Aerts I; Strauss SJ; Thebaud E; Morland B; Nieto AC; Marec-Berard P; Gambart M; Rossig C; Okpara CE; He C; Dutta L; Campbell-Hewson Q
Lancet Oncol; 2021 Sep; 22(9):1312-1321. PubMed ID: 34416158
[TBL] [Abstract][Full Text] [Related]
25. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
Okusaka T; Ikeda K; Kudo M; Finn R; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Mody K; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
J Gastroenterol; 2021 Jun; 56(6):570-580. PubMed ID: 33948712
[TBL] [Abstract][Full Text] [Related]
27. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.
Llovet JM; Vogel A; Madoff DC; Finn RS; Ogasawara S; Ren Z; Mody K; Li JJ; Siegel AB; Dubrovsky L; Kudo M
Cardiovasc Intervent Radiol; 2022 Apr; 45(4):405-412. PubMed ID: 35119481
[TBL] [Abstract][Full Text] [Related]
28. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
[No Abstract] [Full Text] [Related]
29. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
[TBL] [Abstract][Full Text] [Related]
30. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
31. Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.
Yonemori K; Fujiwara K; Hasegawa K; Yunokawa M; Ushijima K; Suzuki S; Shikama A; Minobe S; Usami T; Kim JW; Kim BG; Wang PH; Chang TC; Yamamoto K; Han S; McKenzie J; Orlowski RJ; Miura T; Makker V; Man Kim Y
J Gynecol Oncol; 2024 Mar; 35(2):e40. PubMed ID: 38302725
[TBL] [Abstract][Full Text] [Related]
32. Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report.
Liu Z; Li X; He X; Xu Y; Wang X
BMC Cancer; 2019 Nov; 19(1):1062. PubMed ID: 31703571
[TBL] [Abstract][Full Text] [Related]
33. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
[TBL] [Abstract][Full Text] [Related]
34. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
Ando Y; Kawaoka T; Suehiro Y; Yamaoka K; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Azakami T; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2020; 98(11):787-797. PubMed ID: 32882687
[TBL] [Abstract][Full Text] [Related]
35. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
[TBL] [Abstract][Full Text] [Related]
36. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
37. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
[No Abstract] [Full Text] [Related]
38. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.
Xu J; Shen J; Gu S; Zhang Y; Wu L; Wu J; Shao G; Zhang Y; Xu L; Yin T; Liu J; Ren Z; Xiong J; Mao X; Zhang L; Yang J; Li L; Chen X; Wang Z; Gu K; Chen X; Pan Z; Ma K; Zhou X; Yu Z; Li E; Yin G; Zhang X; Wang S; Wang Q
Clin Cancer Res; 2021 Feb; 27(4):1003-1011. PubMed ID: 33087333
[TBL] [Abstract][Full Text] [Related]
39. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Alekseev B; Rha SY; Merchan J; Goh JC; Lalani AA; De Giorgi U; Melichar B; Hong SH; Gurney H; Méndez-Vidal MJ; Kopyltsov E; Tjulandin S; Gordoa TA; Kozlov V; Alyasova A; Winquist E; Maroto P; Kim M; Peer A; Procopio G; Takagi T; Wong S; Bedke J; Schmidinger M; Rodriguez-Lopez K; Burgents J; He C; Okpara CE; McKenzie J; Choueiri TK;
J Clin Oncol; 2024 Apr; 42(11):1222-1228. PubMed ID: 38227898
[No Abstract] [Full Text] [Related]
40. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.
Mei K; Qin S; Chen Z; Liu Y; Wang L; Zou J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]